GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2013-04-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT00509769
- Locations
- 🇺🇸
USO, Dallas, Texas, United States
🇺🇸Lynn Cancer Institute - West, Boca Raton, Florida, United States
🇺🇸Florida Cancer Care, Davie, Florida, United States
A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)
Phase 1
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2007-07-06
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00497497
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00496132
A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT00495612
A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)
Phase 2
Terminated
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2009-04-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00491738
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)
Phase 3
Completed
- Conditions
- Macular EdemaRetinal Vein Occlusion
- Interventions
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 392
- Registration Number
- NCT00485836
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
Phase 3
Completed
- Conditions
- Macular EdemaRetinal Vein Occlusion
- Interventions
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 397
- Registration Number
- NCT00486018
A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)
Phase 3
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 613
- Registration Number
- NCT00485589
A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)
Phase 2
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT00480831
A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab
Withdrawn
- Conditions
- Carcinoma
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00477425
© Copyright 2025. All Rights Reserved by MedPath